bispecific antibodies for myeloma: highlights from ash 2020
Published 3 years ago • 428 plays • Length 2:55Download video MP4
Download video MP3
Similar videos
-
1:45
the advent of bispecific antibodies for multiple myeloma
-
2:33
the role of bispecific antibodies in the treatment of patients with multiple myeloma
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
1:31
bispecific antibodies in the treatment pipeline for myeloma in the uk
-
6:17
myeloma made simple: bispecific antibodies made simple | bispecific antibodies for myeloma treatment
-
6:09
bispecific antibodies | high impact topic (hit)
-
7:40
results of bispecific antibody combination in advanced myeloma | yael cohen, md | asco 2023
-
1:45
using the available repertoire of bispecific antibodies for treating multiple myeloma
-
3:37
bispecific antibodies in multiple myeloma: their current role and the future
-
1:20
a comparison of bispecific antibodies emerging in multiple myeloma
-
1:53
infections following anti-bcma bispecific antibodies for multiple myeloma
-
7:05
developments in the use of bispecific antibodies in myeloma and challenges in this space
-
6:35
the benefits of bispecific antibodies for treating multiple myeloma
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
1:15
safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
-
1:22
risk of infection in patients with multiple myeloma treated with bispecific antibodies
-
1:47
immunoprism: a platform study investigating bispecific antibodies in smoldering multiple myeloma
-
1:01
car-t: myeloma toxicities
-
2:56
the exciting future of bispecific antibodies
-
1:01
considerations to optimize the outcomes of bispecific antibody treatment in patients with myeloma